| Name | Motolimod |
| Description | Motolimod (VTX-378) (VTX-2337) is an effective and specific Toll-like receptor (TLR) 8 agonist (EC50: 100 nM), > 50-fold selectivity over TLR7. |
| Cell Research | PBMCs or purified NK cells are prepared as previously described, and the purity of NK cells was approximately 99%. NK cell-mediated cytotoxicity is assessed by Calcein-AM release from labeled target cells. In brief, PBMCs or purified NK cells are cultured for 48 hours in RPMI medium in the presence of VTX-2337 (167 or 500 nmol/L) before incubation with target cells. |
| Kinase Assay | The activity of specific TLR agonists is assessed using the secretory embryonic alkaline phosphatase (SEAP) reporter gene that is linked to NF-κB activation in response to TLR stimulation. Measurement of SEAP activity using the Quanti-blue substrate (InvivoGen) after TLR agonist treatment is carried out. |
| In vitro | Motolimodinduces the production of both TNFα (EC50: 140 nM) and IL-12 (EC50: 120 nM) in PBMCs. In mDCs and monocytes, Motolimodspecifically induces the production of IL-12 and TNFα via NF-κB activation. Motolimodalso induces IFNγ production from NK cells, enhances the lytic function of NK cells and augments ADCC. |
| In vivo | In ovarian cancer mouse model, TX-2337 augments the effect of pegylated liposomal doxorubicin (PLD). |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : < 1 mg/mL (insoluble or slightly soluble)
Ethanol : 12 mg/mL (26.2 mM)
DMSO : 51 mg/mL (111.2 mM)
|
| Keywords | inhibit | VTX378 | VTX 2337 | VTX2337 | Inhibitor | Toll-like Receptor (TLR) | VTX 378 | Motolimod |
| Inhibitors Related | Polyinosinic-polycytidylic acid sodium | CU-CPD107 | Imiquimod hydrochloride | Hydroxychloroquine | Chloroquine phosphate | Hydroxychloroquine sulfate | Chloranil | Chloroquine | CU-115 | Imiquimod | TLR3-IN-1 | Resiquimod |
| Related Compound Libraries | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Ovarian Cancer Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
United States
